DaVita (NYSE:DVA) Releases FY 2026 Earnings Guidance

05 May 2026, 21:32 by Doug Wharley · The Cerbat Gem

DaVita (NYSE:DVA – Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 14.100-15.200 for the period, compared to the consensus EPS estimate of 14.130. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on DVA shares. Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. TD Cowen reaffirmed a “hold” rating on shares of DaVita in a research report on Tuesday, February 3rd. Truist Financial set a $158.00 target price on shares of DaVita in a research note on Thursday, February 5th. UBS Group lifted their price target on shares of DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Finally, Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, DaVita has an average rating of “Hold” and a consensus target price of $155.80.

Get Our Latest Research Report on DaVita

DaVita Price Performance

NYSE:DVA traded up $2.90 during midday trading on Tuesday, reaching $156.98. 1,992,540 shares of the company traded hands, compared to its average volume of 610,383. DaVita has a twelve month low of $101.00 and a twelve month high of $159.42. The company has a fifty day moving average price of $151.30 and a 200 day moving average price of $131.73. The firm has a market capitalization of $10.49 billion, a price-to-earnings ratio of 15.84, a price-to-earnings-growth ratio of 0.54 and a beta of 0.84.

DaVita (NYSE:DVA – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The business had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. During the same quarter last year, the company earned $2.00 EPS. The company’s revenue for the quarter was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities research analysts forecast that DaVita will post 14.16 earnings per share for the current fiscal year.

Trending Headlines about DaVita

Here are the key news stories impacting DaVita this week:

Positive Sentiment: Q1 earnings and revenue beat street estimates; EPS $2.87 vs. consensus and revenue topped expectations, showing operational strength. DaVita HealthCare (DVA) Tops Q1 Earnings and Revenue Estimates
Positive Sentiment: Company raised its annual adjusted profit forecast, citing steady/strong demand for dialysis services — a clear driver for higher forward earnings expectations. DaVita lifts annual profit forecast on strong demand for dialysis services
Positive Sentiment: Company commentary and PR emphasize clinical performance and operating rigor, reinforcing confidence in recurring dialysis revenue and margin durability. DaVita Inc. 1st Quarter 2026 Results
Neutral Sentiment: Guidance range of $14.10–$15.20 roughly lines up with consensus (≈$14.13 midpoint), so while management raised the top-line outlook, the midpoint is close to expectations — limits the surprise factor. MarketBeat Q1 release & guidance
Neutral Sentiment: Elevated intraday trading volume (~2M vs. ~985k average) indicates increased attention and liquidity, which can amplify price moves in either direction. DaVita’s Q1 CY2026 beats on revenue
Negative Sentiment: Despite the beat, reported net margin was modest (≈5.5%) and the company showed a negative return on equity figure, which may concern some investors about capital structure or one-time items; watch commentary from the call for drivers. DaVita HealthCare: Q1 Earnings Snapshot

Institutional Trading of DaVita

Large investors have recently added to or reduced their stakes in the business. Canada Pension Plan Investment Board bought a new position in shares of DaVita in the second quarter valued at $43,000. Caitlin John LLC acquired a new stake in shares of DaVita during the fourth quarter worth $34,000. iSAM Funds UK Ltd acquired a new position in shares of DaVita in the 3rd quarter valued at $46,000. Kestra Advisory Services LLC purchased a new position in DaVita in the 4th quarter worth about $45,000. Finally, AlphaCentric Advisors LLC acquired a new stake in DaVita during the 4th quarter worth about $50,000. 90.12% of the stock is currently owned by institutional investors.

About DaVita

(Get Free Report)

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.